Sensus Healthcare, Inc. (SRTS)
| Market Cap | 55.73M |
| Revenue (ttm) | 37.56M |
| Net Income (ttm) | -848,000 |
| Shares Out | 16.44M |
| EPS (ttm) | -0.05 |
| PE Ratio | n/a |
| Forward PE | 90.40 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 113,098 |
| Open | 3.280 |
| Previous Close | 3.300 |
| Day's Range | 3.210 - 3.430 |
| 52-Week Range | 3.030 - 9.329 |
| Beta | 1.35 |
| Analysts | Strong Buy |
| Price Target | 8.00 (+135.99%) |
| Earnings Date | Aug 7, 2025 |
About SRTS
Sensus Healthcare, Inc. operates as a medical device company that manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 V... [Read more]
Financial Performance
In 2024, Sensus Healthcare's revenue was $41.81 million, an increase of 71.31% compared to the previous year's $24.41 million. Earnings were $6.65 million, an increase of 1270.52%.
Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for SRTS stock is "Strong Buy." The 12-month stock price target is $8.0, which is an increase of 135.99% from the latest price.
News
Sensus Healthcare, Inc. Investors: Company Investigated by the Portnoy Law Firm
Investors can contact the law firm at no cost to learn more about recovering their losses
SRTS Investors Have Opportunity to Join Sensus Healthcare, Inc. Fraud Investigation with the Schall Law Firm
LOS ANGELES--(BUSINESS WIRE)---- $SRTS--SRTS Investors Have Opportunity to Join Sensus Healthcare, Inc. Fraud Investigation with the Schall Law Firm.
Sensus Healthcare, Inc. (SRTS) Q2 2025 Earnings Call Transcript
Sensus Healthcare, Inc. (NASDAQ:SRTS) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants Javier Rampolla - Chief Financial Officer Joseph C. Sardano - Co-Founder, Chairma...
Sensus Healthcare Reports Second Quarter 2025 Financial Results
BOCA RATON, Fla.--(BUSINESS WIRE)---- $SRTS--Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective trea...
Sensus Healthcare to Report Second Quarter 2025 Financial Results and Hold Business Update Conference Call on August 7
BOCA RATON, Fla.--(BUSINESS WIRE)--Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for...
Receipt of MDSAP Certification for Sensus Healthcare's Full SRT Product Portfolio to Streamline and Accelerate International Sales Efforts
BOCA RATON, Fla.--(BUSINESS WIRE)---- $SRTS--Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective trea...
Sensus Healthcare Engages Radiology Oncology Systems (ROS) as Primary Distribution Partner for its SRT Systems to Radiation Oncologists
BOCA RATON, Fla.--(BUSINESS WIRE)---- $SRTS--Sensus Healthcare, Inc. (Nasdaq: SRTS) (Sensus or the Company), a medical device company specializing in highly effective, non-invasive, minimally-invasive...
Sensus Healthcare, Inc. (SRTS) Q1 2025 Earnings Call Transcript
Sensus Healthcare, Inc. (NASDAQ:SRTS) Q1 2025 Earnings Conference Call May 15, 2025 4:30 PM ET Company Participants Tirth Patel - Alliance Advisors, IR Joe Sardano - Chairman and CEO Michael Sardano ...
Sensus Healthcare Reports First Quarter 2025 Financial Results
BOCA RATON, Fla.--(BUSINESS WIRE)---- $SRTS--Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective trea...
Sensus Healthcare Celebrates Skin Cancer Awareness Month by Promoting Awareness and Spotlighting its Patient-Friendly, Non-Invasive Treatments
BOCA RATON, Fla.--(BUSINESS WIRE)--May is Skin Cancer Awareness Month and Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-inv...
Sensus Healthcare to Report First Quarter 2025 Financial Results and Hold Business Update Conference Call on May 15
BOCA RATON, Fla.--(BUSINESS WIRE)--Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for...
Sensus Healthcare to Participate in the 37th Annual ROTH Conference
BOCA RATON, Fla.--(BUSINESS WIRE)--Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for...
Sensus Healthcare to Showcase Commercial and Late-Stage Products at the American Academy of Dermatology Annual Meeting
BOCA RATON, Fla.--(BUSINESS WIRE)---- $SRTS--Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective trea...
Sensus Healthcare Announces Publication of Study at Tri Service Military Hospital in Taiwan Demonstrating Efficacy of SRT-100® in Preventing Keloid Recurrence
BOCA RATON, Fla.--(BUSINESS WIRE)--Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for...
Sensus Healthcare Buys Back Shares
BOCA RATON, Fla.--(BUSINESS WIRE)--Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for...
Sensus Healthcare: A Tough Q1 2025 Awaits Ahead
Q4 2024 showed a significant miss in profitability despite a 4% YoY sales growth; gross profit margin dropped due to a one-time discount for a new big client. The FDA initiatives are interesting, but ...
Sensus Healthcare, Inc. (SRTS) Q4 2024 Earnings Call Transcript
Sensus Healthcare, Inc. (NASDAQ:SRTS) Q4 2024 Earnings Conference Call February 5, 2025 4:30 PM ET Company Participants Tirth Patel - Alliance Advisors, IR Joe Sardano - Chairman and CEO Michael Sard...
Sensus Healthcare Reports Fourth Quarter and Full Year 2024 Financial Results
BOCA RATON, Fla.--(BUSINESS WIRE)--Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for...
Sensus Healthcare to Present at The Microcap Conference 2025
BOCA RATON, Fla.--(BUSINESS WIRE)--Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for...
Sensus Healthcare to Report 2024 Fourth Quarter and Full Year Financial Results and Hold Business Update Conference Call on Wednesday, February 5, 2025
BOCA RATON, Fla.--(BUSINESS WIRE)---- $SRTS--Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective trea...
Pompano Veterinary Oncology Partners with Sensus Healthcare to Provide First Superficial Radiotherapy Services in a Mobile Configuration
Full-service medical oncology practice to pioneer the use of SRT to treat companion animals for both home and veterinary clinic visits
REVISED - Sensus Healthcare Reports Third Quarter 2024 Financial Results With Revenues More than Doubling Versus 2023 Third Quarter
This revised news release replaces the one issued on November 14, 2024, contains several non-financial changes throughout and removes the name of and references to a new customer, at the customer's re...
Sensus Healthcare: Q3 Results Showed That The Stock Is Undervalued
Sensus Healthcare's Q3 results exceeded expectations with 127% YoY revenue growth and EPS of $0.07, showcasing strong demand recovery and effective management strategies. The Fair Deal Agreement and n...
Sensus Healthcare, Inc. (SRTS) Q3 2024 Earnings Call Transcript
Sensus Healthcare, Inc. (SRTS) Q3 2024 Earnings Call Transcript
Sensus Healthcare Reports Third Quarter 2024 Financial Results With Revenues More than Doubling Versus 2023 Third Quarter
Revenues of $8.8 million compare with $3.9 million in the prior-year quarter, adjusted EBITDA (a non-GAAP measure) of $1.6 million compares with negative $1.7 million a year ago Signed a Fair Deal Agr...